Lilly Sues Invagen Over Osteoporosis Drug Evista

Law360, New York (January 29, 2009, 12:00 AM EST) -- Eli Lilly & Co. has sued InvaGen Pharmaceuticals Inc. over its attempt to make a generic version of the osteoporosis drug Evista, a Lilly drug at the center of another long-running dispute with rival Ariad Pharmaceuticals Inc.

In a complaint filed Wednesday in the U.S. District Court for the Southern District of Indiana, Lilly claims InvaGen's abbreviated new drug application to the U.S. Food and Drug Administration to make generic Evista infringes three of its patents.

Evista is approved to treat and prevent osteoporosis in postmenopausal...
To view the full article, register now.